Sotagliflozin Clinical Trials

4 actively recruiting trials across 2 locations

▼ -1 trial since July 2026

Also known as: INPEFA, SAR439954/LX4211

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

University of Pennsylvania1
University of Dundee1
Steno Diabetes Center Copenhagen1
Alessandro Doria1

Indications

Heart Disease4
Diabetes3
Heart Failure3
Type 1 Diabetes2
Cardiac Sarcoidosis1

Other2 trials

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Phase 3

Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

Phase 2

Stanford, California1 trial

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Stanford University Medical Center

Phase 3

Philadelphia, Pennsylvania1 trial

Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression

University of Pennsylvania

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.